Neutral impactSector
Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today
CNBC-TV18 1 hr ago·3 Nov 2026, 2:44 am
Granules India is set to react to its Q2 results, with analysts highlighting a key shift in its growth drivers. While the company's US formulations business is showing signs of softening growth, this slowdown is being offset by strength in its European active pharmaceutical ingredients (API) and rest-of-world segments.
This development is significant for investors as it signals a strategic pivot in the company's revenue composition. A slowdown in the US market is a common concern for Indian pharma firms, but Granules' ability to find growth in other regions suggests resilience. It indicates the company is successfully diversifying its revenue streams beyond its traditional markets.
Investors should monitor the management's commentary on the outlook for the US business and the sustainability of growth in the European and rest-of-world markets. This will help determine if the current growth momentum can be maintained in the coming quarters.
Excerpt from CNBC-TV18
Published On Nov 3, 2026 | 08:14 IST Last Updated On Nov 3, 2026 | 08:14 IST Analysts have cited signs of softening growth in Granules India's US formulations business. That slowdown in growth is compensated by Europe's active pharmaceutical ingredients (API) and rest of world businesses. Five pharmaceutical and…Read the original at CNBC-TV18
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Granules India (GRANULES).
- Category: Sector.
Why it matters
A routine update for Granules India. Use the price and stock snapshot to gauge how the market is responding.
